Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Blood (2013) 122 (21): 2729.

https://doi.org/10.1182/blood.V122.21.2729.2729

Published: 2013

Journal Articles

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Naoto Takahashi, MD, PhD, Kenichi Ishizawa, MD, Chiaki Nakaseko, M.D., Ph.D., Yukio Kobayashi, MD, PhD, Kazuteru Ohashi, MD, FACP, Yasunori Nakagawa, MD, Kazuhito Yamamoto, M.D., Ph.D., Koichi Miyamura, MD, PhD, Masafumi Taniwaki, MD, PhD, Masaya Okada, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Atsushi Shibata, BE, Yosuke Fujii, PhD, Chiho Ono, PhD, Kazunori Ohnishi, MD, PhD

Blood (2013) 122 (21): 2736.

https://doi.org/10.1182/blood.V122.21.2736.2736

Published: 2013

Journal Articles

Prognostic Value Of GELF Criteria and FLIPI2 For Newly Diagnosed Follicular Lymphoma Receiving R-CHOP Chemotherapy

Satsuki Murakami, M.D., Harumi Kato, M.D, Ph.D., Kazuhito Yamamoto, M.D., Ph.D., Hirofumi Taji, M.D., Ph.D., Daiki Hirano, M.D., Yasushi Yatabe, M.D., Ph.D., Shigeo Nakamura, M.D., Ph.D., Tomohiro Kinoshita, MD, PhD

Blood (2013) 122 (21): 4368.

https://doi.org/10.1182/blood.V122.21.4368.4368

Published: 2013

Journal Articles

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Takashi Ishida, MD, PhD, Michinori Ogura, MD, PhD, Kiyohiko Hatake, Masafumi Taniwaki, MD, PhD, Kiyoshi Ando, MD, PhD, Kensei Tobinai, MD, PhD, Katsuya Fujimoto, MD, PhD, Kazuhito Yamamoto, M.D., Ph.D., Toshihiro Miyamoto, MD, PhD, Naokuni Uike, MD, PhD, Mitsune Tanimoto, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kenichi Ishizawa, MD, PhD, Junji Suzumiya, MD, PhD, Hiroshi Inagaki, MD, PhD, Kazuo Tamura, MD, PhD, Shiro Akinaga, PhD, Masao Tomonaga, MD, PhD, Ryuzo Ueda, MD, PhD

Blood (2012) 120 (21): 795.

https://doi.org/10.1182/blood.V120.21.795.795

Published: 2012

Journal Articles

Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy

Harumi Kato, M.D., Ph.D., Takeshi Kodaira, M.D., Ph.D., Kazuhito Yamamoto, M.D., Ph.D., Yukihiko Oshima, M.D., Ph.D., Yasuhiro Oki, M.D., Hiroyuki Tachibana, M.D., Hirofumi Taji, M.D., Ph.D., Satsuki Murakami, M.D., Daiki Hirano, M.D., Natsuo Tomita, M.D., Ph.D., Yasushi Yatabe, M.D., Ph.D., Shigeo Nakamura, M.D., Ph.D., Tomohiro Kinoshita, M.D., Ph.D.

Blood (2012) 120 (21): 3665.

https://doi.org/10.1182/blood.V120.21.3665.3665

Published: 2012

Journal Articles

Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy.

Yasuhiro Oki, MD, Keitaro Matsuo, M.D., Ph.D., Harumi Kato, M.D., Kazuhito Yamamoto, M.D., Ph.D., Yoshitoyo Kagami, M.D., Ph.D., Yasuo Morishima, M.D., Ph.D.

Blood (2007) 110 (11): 1569.

https://doi.org/10.1182/blood.V110.11.1569.1569

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Prognostic Value Of GELF Criteria and FLIPI2 For Newly Diagnosed Follicular Lymphoma Receiving R-CHOP Chemotherapy

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy

Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy.

Email alerts

ASH Publications

American Society of Hematology

Update search

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Prognostic Value Of GELF Criteria and FLIPI2 For Newly Diagnosed Follicular Lymphoma Receiving R-CHOP Chemotherapy

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy

Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only